Last reviewed · How we verify
Aldosterone Antagonists - spironolactone
Aldosterone Antagonists - spironolactone is a Small molecule drug developed by NHS Greater Glasgow and Clyde. It is currently in Phase 1 development.
Spironolactone is a small molecule mineralocorticoid receptor antagonist used to treat various conditions, including hypertension, cardiovascular disease, and diabetes. It is classified as an antagonist and has been studied in clinical trials for its potential effects on COVID-19 severity and mortality.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Aldosterone Antagonists - spironolactone |
|---|---|
| Sponsor | NHS Greater Glasgow and Clyde |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing (PHASE4)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- The Effect of SAAE on Vascular Endothelial Function in PA Patients
- Dapagliflozin With or Without Spironolactone for HFpEF (PHASE2, PHASE3)
- Fibrosis and the Fontan (PHASE1, PHASE2)
- Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation (EARLY_PHASE1)
- The Effect of SAAE on Ventricular Remodeling in PA Patients (NA)
- Spironolactone in the Treatment of Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldosterone Antagonists - spironolactone CI brief — competitive landscape report
- Aldosterone Antagonists - spironolactone updates RSS · CI watch RSS
- NHS Greater Glasgow and Clyde portfolio CI
Frequently asked questions about Aldosterone Antagonists - spironolactone
What is Aldosterone Antagonists - spironolactone?
Who makes Aldosterone Antagonists - spironolactone?
What development phase is Aldosterone Antagonists - spironolactone in?
Related
- Manufacturer: NHS Greater Glasgow and Clyde — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing